NVS logo

NVS
Novartis AG

6,844
Mkt Cap
$278.26B
Volume
1.41M
52W High
$170.46
52W Low
$111.06
PE Ratio
21.53
NVS Fundamentals
Price
$152.01
Prev Close
$151.76
Open
$151.56
50D MA
$149.70
Beta
0.30
Avg. Volume
1.5M
EPS (Annual)
$7.25
P/B
7.53
Rev/Employee
$728,224.22
$293,740.89
Loading...
Loading...
News
all
press releases
Cancer Stocks That Are Advancing the Future of Oncology Care
Oncology innovation is accelerating as AI, immunotherapy and targeted drugs drive growth for cancer-focused biotech and pharma stocks.
News Placeholder
More News
News Placeholder
Ralph Baric And UNC's Biodefense Contract Racket Exposed
Ralph Baric And UNC's Biodefense Contract Racket Exposed Authored by Paul D. Thacker via The DisInformation Chronicle, DLA Piper wants to get you, I was told, from a source in DC over the weekend...
News Placeholder
Implied Volatility Surging for Novartis Stock Options
Investors need to pay close attention to NVS stock based on the movements in the options market lately.
News Placeholder
Hassett forecasts 4% growth, says AI boom and tax incentives driving US investment surge
Wall Street's rally is increasingly being tied to a mix of artificial intelligence investment, corporate tax incentives and a wave of factory construction reshaping the U.S. economy.White House...
News Placeholder
Principal Financial Group Inc. Reduces Holdings in Novartis AG $NVS
Principal Financial Group Inc. lowered its holdings in shares of Novartis AG (NYSE:NVS - Free Report) by 13.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,809,158 shares of the company's stock after...
News Placeholder
Triasima Portfolio Management inc. Acquires 32,620 Shares of Novartis AG $NVS
Triasima Portfolio Management inc. grew its holdings in Novartis AG (NYSE:NVS - Free Report) by 185.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 50,175 shares of the company's stock after purchasing an additional 32,620 s...
News Placeholder
Oppenheimer & Co. Inc. Reduces Position in Novartis AG $NVS
Oppenheimer & Co. Inc. lessened its position in shares of Novartis AG (NYSE:NVS - Free Report) by 39.7% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 22,226 shares of the company's stock after selling 14,618 shares durin...
News Placeholder
Wilkins Investment Counsel Inc. Sells 17,565 Shares of Novartis AG $NVS
Wilkins Investment Counsel Inc. cut its holdings in Novartis AG (NYSE:NVS - Free Report) by 13.1% in the 4th quarter, according to the company in its most recent filing with the Securities and...
News Placeholder
Alnylam Q1 Earnings Beat Estimates, Amvuttra Sales Drive Y/Y Growth
ALNY beats Q1 earnings and revenue estimates as Amvuttra sales surge 187%, driving 96% revenue growth and offsetting declines in collaborator revenue and Onpattro sales.
News Placeholder
November 20th Options Now Available For Novartis (NVS)
Investors in Novartis (Symbol: NVS) saw new options become available today, for the November 20th expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 203 days until expiration the newly available contracts rep...
<
1
2
...
>

Compact View

Mini-Chart
Sentiment
Not available
Message Volume
Not available